Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eftilagimod Alpha + Paclitaxel in HR+ Metastatic Breast Cancer (AIPAC-002)
NCT04252768Phase 1Withdrawn
- Sponsor
- Immutep Limited
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
01
Overview
Phase 1, open-label, single-arm trial of eftilagimod alpha in breast cancer, sponsored by Immutep Limited. Primary endpoint: Safety and tolerability profile of efti in combination with weekly paclitaxel both given the same day at 12 months. Planned start Jun 2023; status: withdrawn.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04252768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252768.